Luedtke D - Search Results

1

Pharmacokinetics of Nintedanib in Subjects With Hepatic Impairment.

Marzin K, Kretschmar G, Luedtke D, Kraemer S, Kuelzer R, Schlenker-Herceg R, Schmid U, Schnell D, Dallinger C. Marzin K, et al. Among authors: luedtke d. J Clin Pharmacol. 2018 Mar;58(3):357-363. doi: 10.1002/jcph.1025. Epub 2017 Nov 6. J Clin Pharmacol. 2018. PMID: 29106740 Free PMC article. Clinical Trial.

2

Pharmacokinetics and safety of olodaterol administered with the Respimat Soft Mist inhaler in subjects with impaired hepatic or renal function.

Kunz C, Luedtke D, Unseld A, Hamilton A, Halabi A, Wein M, Formella S. Kunz C, et al. Among authors: luedtke d. Int J Chron Obstruct Pulmon Dis. 2016 Mar 18;11:585-95. doi: 10.2147/COPD.S94234. eCollection 2016. Int J Chron Obstruct Pulmon Dis. 2016. PMID: 27051282 Free PMC article.

3

Effects of Ketoconazole and Rifampicin on the Pharmacokinetics of Nintedanib in Healthy Subjects.

Luedtke D, Marzin K, Jungnik A, von Wangenheim U, Dallinger C. Luedtke D, et al. Eur J Drug Metab Pharmacokinet. 2018 Oct;43(5):533-541. doi: 10.1007/s13318-018-0467-9. Eur J Drug Metab Pharmacokinet. 2018. PMID: 29500603 Free PMC article. Clinical Trial.

4

Comprehensive biomarker and modeling approach to support dose finding for BI 836880, a VEGF/Ang-2 inhibitor.

Keller S, Kunz U, Schmid U, Beusmans J, Büchert M, He M, Jayadeva G, Le Tourneau C, Luedtke D, Niessen HG, Oum'hamed Z, Pleiner S, Wang X, Graeser R. Keller S, et al. Among authors: luedtke d. J Transl Med. 2024 Oct 14;22(1):934. doi: 10.1186/s12967-024-05612-x. J Transl Med. 2024. PMID: 39402675 Free PMC article. Clinical Trial.

5

Phase I studies of BI 1015550, a preferential phosphodiesterase 4B inhibitor, in healthy males and patients with idiopathic pulmonary fibrosis.

Maher TM, Schlecker C, Luedtke D, Bossert S, Zoz DF, Schultz A. Maher TM, et al. Among authors: luedtke d. ERJ Open Res. 2022 Oct 24;8(4):00240-2022. doi: 10.1183/23120541.00240-2022. eCollection 2022 Oct. ERJ Open Res. 2022. PMID: 36299369 Free PMC article.

6

Two phase I studies of BI 836880, a vascular endothelial growth factor/angiopoietin-2 inhibitor, administered once every 3 weeks or once weekly in patients with advanced solid tumors.

Le Tourneau C, Becker H, Claus R, Elez E, Ricci F, Fritsch R, Silber Y, Hennequin A, Tabernero J, Jayadeva G, Luedtke D, He M, Isambert N. Le Tourneau C, et al. Among authors: luedtke d. ESMO Open. 2022 Oct;7(5):100576. doi: 10.1016/j.esmoop.2022.100576. Epub 2022 Sep 13. ESMO Open. 2022. PMID: 36108560 Free PMC article. Clinical Trial.

7

Target Actionability Review: a systematic evaluation of replication stress as a therapeutic target for paediatric solid malignancies.

Keller KM, Krausert S, Gopisetty A, Luedtke D, Koster J, Schubert NA, Rodríguez A, van Hooff SR, Stichel D, Dolman MEM, Vassal G, Pfister SM, Caron HN, Stancato LF, Molenaar JJ, Jäger N, Kool M. Keller KM, et al. Among authors: luedtke d. Eur J Cancer. 2022 Feb;162:107-117. doi: 10.1016/j.ejca.2021.11.030. Epub 2021 Dec 25. Eur J Cancer. 2022. PMID: 34963094 Free article. Review.

8

Inhibition of CDK9 by voruciclib synergistically enhances cell death induced by the Bcl-2 selective inhibitor venetoclax in preclinical models of acute myeloid leukemia.

Luedtke DA, Su Y, Ma J, Li X, Buck SA, Edwards H, Polin L, Kushner J, Dzinic SH, White K, Lin H, Taub JW, Ge Y. Luedtke DA, et al. Signal Transduct Target Ther. 2020 Feb 26;5(1):17. doi: 10.1038/s41392-020-0112-3. Signal Transduct Target Ther. 2020. PMID: 32296028 Free PMC article.

9

A delicate balance - The BCL-2 family and its role in apoptosis, oncogenesis, and cancer therapeutics.

Knight T, Luedtke D, Edwards H, Taub JW, Ge Y. Knight T, et al. Among authors: luedtke d. Biochem Pharmacol. 2019 Apr;162:250-261. doi: 10.1016/j.bcp.2019.01.015. Epub 2019 Jan 19. Biochem Pharmacol. 2019. PMID: 30668936 Review.

10

Inhibition of XPO1 enhances cell death induced by ABT-199 in acute myeloid leukaemia via Mcl-1.

Luedtke DA, Su Y, Liu S, Edwards H, Wang Y, Lin H, Taub JW, Ge Y. Luedtke DA, et al. J Cell Mol Med. 2018 Dec;22(12):6099-6111. doi: 10.1111/jcmm.13886. Epub 2018 Sep 14. J Cell Mol Med. 2018. PMID: 30596398 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

15 results

Search Page

Filters